PRC
MNTA

Pearl River Capital’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Pearl River Capital’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-675
Closed -$7K – 950
2018
Q4 		$7K Buy
+675
New +$9.39K 0.03% 664

Other funds holding MNTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Pearl River Capital's MNTA Position: Q1 2019 in Review

Pearl River Capital sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q1 2019, closing a stake of 675 shares — an estimated $7K sold.

Pearl River Capital first reported a position in MNTA in Q4 2018 and held it in 1 quarter. The position peaked at $7K in Q4 2018. 147 funds tracked by Wall St. Rank hold MNTA as of Q1 2019.

  • Pearl River Capital reported no remaining Momenta Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Pearl River Capital sold 675 Momenta Pharmaceuticals, Inc. shares in Q1 2019, an estimated $7K.
  • Pearl River Capital first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2018 and held it in 1 quarter.
  • Pearl River Capital's Momenta Pharmaceuticals, Inc. position peaked at $7K in Q4 2018.
  • 147 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q1 2019.

Based on Pearl River Capital's 13F filing for Q1 2019, filed 2 May 2019.